|
Gene: AURKB |
Gene summary for AURKB |
Gene summary. |
Gene information | Species | Human | Gene symbol | AURKB | Gene ID | 9212 |
Gene name | aurora kinase B | |
Gene Alias | AIK2 | |
Cytomap | 17p13.1 | |
Gene Type | protein-coding | GO ID | GO:0000022 | UniProtAcc | Q96GD4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9212 | AURKB | P2T-E | Human | Esophagus | ESCC | 9.44e-07 | 4.81e-01 | 0.1177 |
9212 | AURKB | P4T-E | Human | Esophagus | ESCC | 1.49e-09 | 3.93e-01 | 0.1323 |
9212 | AURKB | P5T-E | Human | Esophagus | ESCC | 8.56e-12 | 2.77e-01 | 0.1327 |
9212 | AURKB | P8T-E | Human | Esophagus | ESCC | 3.50e-02 | 1.55e-01 | 0.0889 |
9212 | AURKB | P9T-E | Human | Esophagus | ESCC | 6.74e-06 | 2.10e-01 | 0.1131 |
9212 | AURKB | P10T-E | Human | Esophagus | ESCC | 2.02e-06 | 2.30e-01 | 0.116 |
9212 | AURKB | P16T-E | Human | Esophagus | ESCC | 8.40e-04 | 1.55e-01 | 0.1153 |
9212 | AURKB | P17T-E | Human | Esophagus | ESCC | 3.52e-10 | 8.08e-01 | 0.1278 |
9212 | AURKB | P19T-E | Human | Esophagus | ESCC | 5.57e-05 | 9.56e-01 | 0.1662 |
9212 | AURKB | P20T-E | Human | Esophagus | ESCC | 2.18e-03 | 2.45e-01 | 0.1124 |
9212 | AURKB | P21T-E | Human | Esophagus | ESCC | 4.12e-11 | 3.60e-01 | 0.1617 |
9212 | AURKB | P24T-E | Human | Esophagus | ESCC | 5.30e-21 | 6.19e-01 | 0.1287 |
9212 | AURKB | P28T-E | Human | Esophagus | ESCC | 1.33e-02 | 1.58e-01 | 0.1149 |
9212 | AURKB | P31T-E | Human | Esophagus | ESCC | 2.03e-09 | 3.49e-01 | 0.1251 |
9212 | AURKB | P32T-E | Human | Esophagus | ESCC | 2.56e-16 | 5.84e-01 | 0.1666 |
9212 | AURKB | P36T-E | Human | Esophagus | ESCC | 1.12e-05 | 3.33e-01 | 0.1187 |
9212 | AURKB | P37T-E | Human | Esophagus | ESCC | 1.03e-11 | 4.07e-01 | 0.1371 |
9212 | AURKB | P38T-E | Human | Esophagus | ESCC | 1.45e-09 | 5.86e-01 | 0.127 |
9212 | AURKB | P42T-E | Human | Esophagus | ESCC | 2.62e-05 | 2.92e-01 | 0.1175 |
9212 | AURKB | P44T-E | Human | Esophagus | ESCC | 6.93e-04 | 2.60e-01 | 0.1096 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:1904358110 | Skin | cSCC | positive regulation of telomere maintenance via telomere lengthening | 22/4864 | 37/18723 | 1.71e-05 | 2.07e-04 | 22 |
GO:00513043 | Skin | cSCC | chromosome separation | 44/4864 | 96/18723 | 2.05e-05 | 2.40e-04 | 44 |
GO:000008611 | Skin | cSCC | G2/M transition of mitotic cell cycle | 58/4864 | 137/18723 | 2.19e-05 | 2.54e-04 | 58 |
GO:00458413 | Skin | cSCC | negative regulation of mitotic metaphase/anaphase transition | 23/4864 | 40/18723 | 2.37e-05 | 2.72e-04 | 23 |
GO:190198812 | Skin | cSCC | negative regulation of cell cycle phase transition | 94/4864 | 249/18723 | 2.65e-05 | 3.00e-04 | 94 |
GO:003209117 | Skin | cSCC | negative regulation of protein binding | 43/4864 | 94/18723 | 2.68e-05 | 3.03e-04 | 43 |
GO:001094812 | Skin | cSCC | negative regulation of cell cycle process | 108/4864 | 294/18723 | 2.75e-05 | 3.09e-04 | 108 |
GO:00070943 | Skin | cSCC | mitotic spindle assembly checkpoint | 22/4864 | 38/18723 | 3.07e-05 | 3.40e-04 | 22 |
GO:00711733 | Skin | cSCC | spindle assembly checkpoint | 22/4864 | 38/18723 | 3.07e-05 | 3.40e-04 | 22 |
GO:00711743 | Skin | cSCC | mitotic spindle checkpoint | 22/4864 | 38/18723 | 3.07e-05 | 3.40e-04 | 22 |
GO:00330463 | Skin | cSCC | negative regulation of sister chromatid segregation | 24/4864 | 43/18723 | 3.11e-05 | 3.42e-04 | 24 |
GO:00330483 | Skin | cSCC | negative regulation of mitotic sister chromatid segregation | 24/4864 | 43/18723 | 3.11e-05 | 3.42e-04 | 24 |
GO:20008163 | Skin | cSCC | negative regulation of mitotic sister chromatid separation | 24/4864 | 43/18723 | 3.11e-05 | 3.42e-04 | 24 |
GO:000007512 | Skin | cSCC | cell cycle checkpoint | 68/4864 | 169/18723 | 3.37e-05 | 3.67e-04 | 68 |
GO:004483911 | Skin | cSCC | cell cycle G2/M phase transition | 61/4864 | 148/18723 | 3.61e-05 | 3.90e-04 | 61 |
GO:003221217 | Skin | cSCC | positive regulation of telomere maintenance via telomerase | 20/4864 | 34/18723 | 5.14e-05 | 5.28e-04 | 20 |
GO:00315773 | Skin | cSCC | spindle checkpoint | 22/4864 | 39/18723 | 5.32e-05 | 5.38e-04 | 22 |
GO:00070935 | Skin | cSCC | mitotic cell cycle checkpoint | 54/4864 | 129/18723 | 5.99e-05 | 5.87e-04 | 54 |
GO:005197219 | Skin | cSCC | regulation of telomerase activity | 25/4864 | 47/18723 | 6.32e-05 | 6.18e-04 | 25 |
GO:19021003 | Skin | cSCC | negative regulation of metaphase/anaphase transition of cell cycle | 23/4864 | 42/18723 | 6.79e-05 | 6.58e-04 | 23 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AURKB | SNV | Missense_Mutation | c.386N>C | p.Ile129Thr | p.I129T | Q96GD4 | protein_coding | deleterious(0) | possibly_damaging(0.566) | TCGA-D8-A1XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide+tamoxifen | SD | |
AURKB | SNV | Missense_Mutation | rs749454960 | c.745N>T | p.Arg249Cys | p.R249C | Q96GD4 | protein_coding | deleterious(0.02) | benign(0.012) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AURKB | SNV | Missense_Mutation | rs772022668 | c.481N>A | p.Gly161Arg | p.G161R | Q96GD4 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
AURKB | SNV | Missense_Mutation | c.371G>A | p.Arg124His | p.R124H | Q96GD4 | protein_coding | deleterious(0) | possibly_damaging(0.71) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
AURKB | SNV | Missense_Mutation | c.595C>T | p.His199Tyr | p.H199Y | Q96GD4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
AURKB | SNV | Missense_Mutation | rs768656332 | c.897G>T | p.Met299Ile | p.M299I | Q96GD4 | protein_coding | tolerated(0.17) | benign(0) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
AURKB | SNV | Missense_Mutation | rs201709756 | c.1033N>A | p.Ala345Thr | p.A345T | Q96GD4 | protein_coding | deleterious_low_confidence(0.04) | benign(0.015) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
AURKB | SNV | Missense_Mutation | rs780771169 | c.89N>A | p.Arg30Gln | p.R30Q | Q96GD4 | protein_coding | tolerated(0.68) | benign(0.007) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
AURKB | SNV | Missense_Mutation | rs55871613 | c.539N>T | p.Thr180Met | p.T180M | Q96GD4 | protein_coding | deleterious(0.02) | benign(0.228) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AURKB | SNV | Missense_Mutation | novel | c.50N>T | p.Ala17Val | p.A17V | Q96GD4 | protein_coding | tolerated(0.09) | benign(0.003) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9212 | AURKB | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, HISTONE MODIFICATION, DRUGGABLE GENOME, KINASE | ZM-447439 | CHEMBL202721 | ||
9212 | AURKB | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, HISTONE MODIFICATION, DRUGGABLE GENOME, KINASE | inhibitor | 178102344 | TOZASERTIB | |
9212 | AURKB | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, HISTONE MODIFICATION, DRUGGABLE GENOME, KINASE | LINIFANIB | LINIFANIB | ||
9212 | AURKB | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, HISTONE MODIFICATION, DRUGGABLE GENOME, KINASE | PAZOPANIB | PAZOPANIB | ||
9212 | AURKB | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, HISTONE MODIFICATION, DRUGGABLE GENOME, KINASE | inhibitor | CHEMBL495727 | AT-9283 | |
9212 | AURKB | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, HISTONE MODIFICATION, DRUGGABLE GENOME, KINASE | inhibitor | 249565620 | DANUSERTIB | |
9212 | AURKB | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, HISTONE MODIFICATION, DRUGGABLE GENOME, KINASE | CYC116 | |||
9212 | AURKB | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, HISTONE MODIFICATION, DRUGGABLE GENOME, KINASE | inhibitor | CHEMBL3545327 | TTP-607 | |
9212 | AURKB | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, HISTONE MODIFICATION, DRUGGABLE GENOME, KINASE | BAY-613606 | CHEMBL541400 | ||
9212 | AURKB | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, HISTONE MODIFICATION, DRUGGABLE GENOME, KINASE | inhibitor | 249565688 | CHEMBL1765740 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |